683 CD8 T cell repertoire analysis of patients with resectable head and neck cancer enrolled in a phase II neoadjuvant study of α-PD1 administered alone or in combination with α-CTLA4 or α-LAG3
Patrícia Santos(UPMC Hillman Cancer Center), Robert L. Ferris(University of Pittsburgh), Housaiyin Li(University of Pittsburgh), Umamaheswar Duvvuri(City University of New York), Aditi Kulkarni(University of North Carolina at Chapel Hill), Jie Chen(Second People’s Hospital of Yibin), Lazar Vujanović(UPMC Hillman Cancer Center), Seungwon Kim(UPMC Hillman Cancer Center), Dan P. Zandberg(University of Pittsburgh Medical Center)
Cited by 2
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
|Immunity|2020|688
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
|The Lancet Oncology|2021|618
Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
|Cancer Discovery|2013|590